Cardiorenal Benefits of SGLT2 Inhibitors Beyond Diabetes

Text
Sandra Chaparro, MD, a researcher specializing in cardiovascular and renal health, highlighted the expanding role of sodium-glucose co-transporter-2 (SGLT2) inhibitors in reducing cardiorenal risks beyond their established use in diabetes management, according to a June 9, 2026, article published in the American Journal of Managed Care (AJMC). The findings, based on a review of recent clinical trials, suggest these medications may offer protective benefits for patients with heart failure or chronic kidney disease regardless of diabetes status.

Subheading
Cardiorenal Benefits Observed in Non-Diabetic Populations
The AJMC article cited data from multiple randomized controlled trials, including the DAPA-HF and EMPEROR-Reduced studies, which demonstrated that SGLT2 inhibitors such as dapagliflozin and empagliflozin reduced the risk of worsening heart failure and kidney function decline in patients without diabetes. In one trial, participants without diabetes who received dapagliflozin had a 28% lower risk of cardiovascular death or hospitalization for heart failure compared to those receiving a placebo, according to the study’s lead author, Dr. Chaparro.

Text
These results align with broader trends in cardiovascular medicine, where therapies initially developed for diabetes are being re-evaluated for their potential to address comorbid conditions. SGLT2 inhibitors work by reducing glucose reabsorption in the kidneys, which lowers blood sugar levels in diabetic patients. However, their cardiorenal benefits appear to stem from mechanisms beyond glycemic control, including reduced fluid retention, improved myocardial efficiency, and anti-inflammatory effects.

Subheading
Clinical Guidelines Begin to Reflect New Evidence
The American Heart Association (AHA) and the American College of Cardiology (ACC) updated their 2024 guidelines to include SGLT2 inhibitors as a class I recommendation for patients with heart failure with reduced ejection fraction (HFrEF), regardless of diabetes status. The guidelines note that these drugs “significantly lower hospitalization rates and improve survival” in this population, citing evidence from large-scale trials.

Text
Dr. Chaparro emphasized that while the findings are promising, patient selection remains critical. “SGLT2 inhibitors are not a universal solution,” she said in an interview. “They are most effective in patients with specific biomarkers, such as elevated natriuretic peptides or reduced kidney function. We need to balance their benefits against potential side effects, like genital infections or volume depletion.”

Subheading
Ongoing Research and Unanswered Questions
Despite the growing body of evidence, some uncertainties persist. A 2026 meta-analysis published in JAMA Cardiology found that the magnitude of cardiorenal benefits varied by drug class and patient subgroup. For example, while dapagliflozin showed consistent efficacy across trials, empagliflozin’s effects were more pronounced in patients with pre-existing kidney disease.

Text
Additionally, long-term safety data remain limited. The AJMC article noted that while SGLT2 inhibitors are generally well-tolerated, their impact on renal outcomes over 10 years is still under investigation. Researchers are also exploring whether these drugs could prevent cardiorenal decline in high-risk populations, such as those with hypertension or obesity.

Subheading
Implications for Public Health and Treatment Practices
The expansion of SGLT2 inhibitors’ indications has significant implications for public health. Cardiovascular disease and chronic kidney disease affect over 100 million Americans, according to the Centers for Disease Control and Prevention (CDC). If these therapies prove effective in broader populations, they could reduce healthcare costs associated with hospitalizations and dialysis.

Text
However, access barriers persist. Many SGLT2 inhibitors remain expensive, and insurance coverage varies. The AJMC article called for policy reforms to ensure equitable access, particularly for low-income patients with cardiorenal conditions. “These drugs represent a major advance, but their potential can only be realized if patients can afford them,” said Dr. Chaparro.

Subheading
What Comes Next?
Future research will focus on identifying biomarkers to better predict which patients will benefit most from SGLT2 inhibitors. Additionally, studies are underway to evaluate their efficacy in combination with other therapies, such as angiotensin-converting enzyme (ACE) inhibitors or mineralocorticoid receptor antagonists.

Text
For now, clinicians are advised to follow the latest guidelines while remaining cautious about off-label use. “We must continue to monitor real-world outcomes,” Dr. Chaparro said. “The science is evolving rapidly, and what we know today may change as more data emerges.”

Quoted text
“SGLT2 inhibitors are not a universal solution. They are most effective in patients with specific biomarkers, such as elevated natriuretic peptides or reduced kidney function. We need to balance their benefits against potential side effects, like genital infections or volume depletion.”
Source: Sandra Chaparro, MD, as reported in the American Journal of Managed Care, June 9, 2026.